Nastech Pharmaceutical Company today announced that it has been awarded U.S. patent No. 6,894,026, entitled, "Long-acting Oxytocin Analogues for the Treatment and Prevention of Breast Cancer and Psych
Introgen Therapeutics has announced that it was successful in winning the decision regarding its opposition of European Patent 0 390 323 before the European Patent Office (EPO) in which all claims di
Biophan Technologies has announced that the U.S. Patent No. 6,902,290 has been granted to the Company. The patent teaches the
Biota Holdings Limited announced today that it has discovered a new class of orally-effective, potent antivirals against RSV (respiratory syncytial virus) infection. Biota has filed worldwide patents
Bone Care International has announced that the U.S. Patent and Trademark Office has issued to it U.S. Patent Number 6,903,083 entitled "Stabilized hydroxyvitamin D." The patent claims a stabi
Vapotherm has announced the recent publication of three pending U.S. patent applications. Each of these applications represents significant milestones for the Company's intellectual property footprint.
Arena Pharmaceuticals has announced that it was issued U.S. patent number 6,902,902, entitled "Human G Protein-Coupled Receptors and Modulators Thereof for the Treatment of Metabolic-Related Disord
Lorus Therapeutics today announced that its wholly owned subsidiary, GeneSense Technologies Inc. (GeneSense), has received notice from the European Patent Office of its intention to grant GeneSense
Chemokine Therapeutics has announced that it has been granted U.S. Patent No. 6,875,738 relating to the use of its anti-cancer compound, CTCE-9908, in the treatment of cancer and inhibition of angio
CalbaTech announced today that its wholly owned subsidiary, LifeStem has filed a U.S. Patent Application for its Stem Cell Delivery Device. The patent is for the Device and Methods for Treatment of
Date: Tuesday, 9-Jan-2007
MedImmune issued the following statement regarding today's U.S. Supreme Court decision in MedImmune, Inc. vs. Genentech, Inc. et al.:By granting MedImmune's appeal, the U.S. Supreme Court has brought further clarity to the patent litigation process -- specifically, the use of declaratory judgments by licensees of questionable patents.
The Court's decision means MedImmune is free to pursue its complaint regarding non-infringement, invalidity, and unenforceability of the Cabilly II patent. We intend to do so vigorously and are confident that our position will prevail.
We appreciate the support MedImmune's position on this issue received in the amicus briefs filed by various parties, including the U.S. Solicitor General; the General Counsel of the U.S. Patent & Trademark Office; the Generic Pharmaceuticals Association; three intellectual property professors; the Natural Resources Defense Counsel, and legal counsel for Medtronic, Inc.
MedImmune strives to provide better medicines to patients, new medical options for physicians, rewarding careers to employees, and increased value to shareholders. Dedicated to advancing science and medicine to help people live better lives, the company is focused on the areas of infectious diseases, cancer and inflammatory diseases. MedImmune is headquartered in Maryland and has more than 2,500 employees worldwide.
http://www.medimmune.com